News | August 10, 2021
ALS drug RADICAVA holds promise as it completes four years in US
Nearly 6,000 patients have been treated with the drug since 2017
Nearly 6,000 patients have been treated with the drug since 2017
Company working on COVID vaccine INO 4800
It leverages Kite’s Chimeric Antigen Receptors and Appia Bio’s Allogeneic Cell Technology Platform to Develop Off-the-Shelf Cell Therapies
The product can be used by any lab that conducts NGS testing, making precision medicine accessible to all cancer patients
The company posted net profit of Rs.34.24 crores for the period ended June 30, 2020.
Single booster dose at 6 months of NVX-CoV2373 increased wild-type neutralizing antibodies more than 4-fold versus primary vaccination series
Sickle Cell Disease Support Corner developed to create a database of individuals with sickle cell disease
Advances deployment of mRNA technology across vaccines and therapeutics development
This robust growth has come despite the raging pandemic for most part of the quarter
He will be responsible for the company's overall strategy and provide the necessary direction and dynamic leadership to R&D, manufacturing, business development, and commercial operations
Subscribe To Our Newsletter & Stay Updated
